Madrid – September 19, 2026 -- mAbxience and Sandoz have signed a licensing, development, manufacturing and commercialization agreement for a proposed emicizumab biosimilar targeting hemophilia A, a treatment referencing Roche's Hemlibra with an estimated global reference market of USD 5.7 billion.
mAbxience will develop and manufacture the biosimilar at GMP facilities in Spain and Argentina
Under the agreement, mAbxience is responsible for development and manufacturing through its facilities in the two countries. Sandoz will handle global commercialization.
Sandoz secures exclusive global rights excluding three South American markets
Sandoz holds exclusive commercialization rights worldwide, with the exception of Argentina, Uruguay and Paraguay. Financial terms of the deal were not disclosed.
Hemophilia A entry expands mAbxience's rare disease pipeline
Hemophilia A, caused by insufficient or defective factor VIII, accounts for roughly 80% of all hemophilia cases globally. The proposed biosimilar adds a rare disease asset to mAbxience's existing pipeline in oncology, immunology and bone disease.
mAbxience Chief Executive Officer Jurgen Van Broeck said the agreement combines the company's manufacturing platform with Sandoz's commercial reach to accelerate patient access to the treatment.
The deal comes as healthcare systems prepare for a wave of biologic medicines losing patent exclusivity in coming years.